Results 21 to 30 of about 31,452 (261)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Pharmaceutics, 2022
Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance.
Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe, Francesco Sabbatino   +11 more
doaj   +1 more source

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

Molecules, 2019
A promising strategy in cancer immunotherapy is the employment of a bispecific agent that can bind with both tumor markers and immunocytes for recruitment of lymphocytes to tumor sites and enhancement of anticancer immune reactions.
Zhaoyi Li, Yan Hu, Yacong An, Jinhong Duan, Xundou Li, Xian-Da Yang   +5 more
doaj   +1 more source

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Frontiers in Oncology, 2020
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE molecules.
Omid Vafa, Nathan D. Trinklein
doaj   +1 more source

Design and engineering of bispecific antibodies: insights and practical considerations

Frontiers in Bioengineering and Biotechnology
Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding activity, which permits simultaneous targeting of antigens and synergistic binding effects beyond what can be obtained even with combinations of conventional ...
Andreas V. Madsen, Lasse E. Pedersen, Peter Kristensen, Steffen Goletz   +3 more
doaj   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Frontiers in Oncology
IntroductionAlthough checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options.
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Miguel F. Sanmamed, Valentina Gambardella, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler   +24 more
doaj   +1 more source

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules

Antibodies, 2022
Bispecific T cell receptor (TCR)-based molecules capable of redirecting and activating T cells towards tumor cells represent a novel and promising class of biotherapeutics for the treatment of cancer. Usage of TCRs allows for targeting of intracellularly
Janine Dilchert, Martin Hofmann, Felix Unverdorben, Roland Kontermann, Sebastian Bunk   +4 more
doaj   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Reconstructing enzyme evolution by protein engineering

FEBS Letters, EarlyView.
Natural enzyme evolution can be retraced by protein engineering methods such as directed evolution, rational design, and ancestral sequence reconstruction. These approaches reveal how enzymes emerged from ligand‐binding scaffolds, developed varying substrate preferences, formed oligomeric complexes, adapted to environmental changes, and evolved novel ...
Lukas Drexler, Markus R. Busch, Reinhard Sterner   +2 more
wiley   +1 more source